(Q42276927)

19 October 2017

Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia (English)

1 reference

19 October 2017

0 references

E Leitersdorf

1

1 reference

19 October 2017

E N Muratti

series ordinal

2

1 reference

19 October 2017

O Eliav

series ordinal

3

1 reference

19 October 2017

T K Peters

series ordinal

4

1 reference

19 October 2017

language of work or name

English

0 references

publication date

1 July 1995

1 reference

American Journal of Cardiology

19 October 2017

1 reference

19 October 2017

76

1 reference

19 October 2017

84A-88A

1 reference

19 October 2017

2

1 reference

Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Combination drug therapy for familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Effects of combined bezafibrate-simvastatin appraised in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

More on rifampin prophylaxis against Haemophilus influenzae b in day-care facilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980025-6

10.1016/S0002-9149(05)80025-6

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference